AI Is Rewriting Drug Discovery
The $2.5 billion market for AI-driven drug discovery is forcing pharmaceutical companies and universities to abandon their old playbooks entirely.
Molekula Blog
The $2.5 billion market for AI-driven drug discovery is forcing pharmaceutical companies and universities to abandon their old playbooks entirely.
Chemists spend half their time searching outdated databases. Here's why the industry's dominant tools are failing researchers—and what needs to change.
When Richmond Sarpong was a kid in Ghana, he watched his father distribute ivermectin to treat river blindness. Seeing that drug work changed his life. Today at UC Berkeley, Sarpong synthesizes complex molecules and figures out how computers can help chemists do it faster.
From Roche to building Molekula.ai, an AI synthesis assistant that understands molecular structures instead of keywords.